Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle

References

• Hung CM, Garcia-Haro L, Sparks CA, Guertin DA. mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol 2012; 4:a008771; PMID:23124837
   PubMed Web of Science ®Google Scholar
• Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23:3151-71; PMID:15094765; http://dx.doi.org/10.1038/sj.onc.1207542
   PubMed Web of Science ®Google Scholar
• Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21:297-308; PMID:22439925; http://dx.doi.org/10.1016/j.ccr.2012.02.014
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging 2011; 3:1130-41; PMID:22246147
   PubMedGoogle Scholar
• Foster DA. Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochim Biophys Acta 2009; 1791:949-55; PMID:19264150; http://dx.doi.org/10.1016/j.bbalip.2009.02.009
   PubMed Web of Science ®Google Scholar
• Sun SY. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett 2013; 340:1-8; PMID:23792225; http://dx.doi.org/10.1016/j.canlet.2013.06.017
   PubMed Web of Science ®Google Scholar
• Gadir N, Jackson DN, Lee E, Foster DA. Defective TGF-b signaling sensitizes human cancer cells to rapamycin. Oncogene 2008; 27:1055-62; PMID:17700525; http://dx.doi.org/10.1038/sj.onc.1210721
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Mukhopadhyay S, Tung K, Patel D, Foster DA. Rapamycin-induced G1 cell cycle arrest employs both TGF-b and Rb pathways. Cancer Lett 2015; 360:134-40; PMID:25659819; http://dx.doi.org/10.1016/j.canlet.2015.01.043
   PubMed Web of Science ®Google Scholar
• Le Gendre O, Sookdeo A, Duliepre SA, Utter M, Frias M, Foster DA. Suppression of AKT Phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells. Mol Cancer Res 2013; 11:474-81; PMID:23443316; http://dx.doi.org/10.1158/1557-3125.ADVBC-A113
   PubMed Web of Science ®Google Scholar
• Saqcena M, Menon D, Patel D, Mukhopadhyay S, Chow V, Foster DA. Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle. PLoS One 2013; 8:e74157; PMID:23977397; http://dx.doi.org/10.1371/journal.pone.0074157
   PubMed Web of Science ®Google Scholar
• Foster DA, Gadir N. Can defective TGF-b signaling be an Achilles heel in human cancer?. Chinese J Cancer 2008; 27:882-4; PMID:18710627
   PubMedGoogle Scholar
• Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22:159-68; PMID:16603397 http://dx.doi.org/10.1016/j.molcel.2006.03.029
   PubMed Web of Science ®Google Scholar
• Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol 2009; 29:1411-20; PMID:19114562; http://dx.doi.org/10.1128/MCB.00782-08
   PubMed Web of Science ®Google Scholar
• Chen Y, Zheng Y, Foster DA. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 2003; 22:3937-42; PMID:12813467; http://dx.doi.org/10.1038/sj.onc.1206565
   PubMed Web of Science ®Google Scholar
• Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001; 294:1942-5; PMID:11729323; http://dx.doi.org/10.1126/science.1066015
   PubMed Web of Science ®Google Scholar
• Yellen P, Saqcena M, Salloum D, Feng J, Preda A, Xu L, Rodrik-Outmezguine V, Foster DA. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 2011; 10:3948-56; PMID:22071574; http://dx.doi.org/10.4161/cc.10.22.18124
   PubMed Web of Science ®Google Scholar
• Yellen P, Chatterjee A, Preda A, Foster DA. Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-b-dependent G1 cell cycle arrest. Cancer Lett 2013; 333:239-43; PMID:23376634; http://dx.doi.org/10.1016/j.canlet.2013.01.041
   PubMed Web of Science ®Google Scholar
• Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005; 433:477-80; PMID:15690031; http://dx.doi.org/10.1038/nature03205
   PubMed Web of Science ®Google Scholar
• Saqcena M, Mukhopadhyay S, Hosny C, Alhamed A, Chatterjee A, Foster DA. Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs. Oncogene 2015; 34:2672-80; PMID:25023699; http://dx.doi.org/10.1038/onc.2014.207
   PubMed Web of Science ®Google Scholar
• Salloum D, Mukhopadhyay S, Tung K, Polonetskaya A, Foster DA. Mutant Ras elevates dependence on serum lipids and creates a synthetic lethality for rapamycin. Mol Cancer Ther 2014; 13:733-41; PMID:24435447; http://dx.doi.org/10.1158/1535-7163.MCT-13-0762
   PubMed Web of Science ®Google Scholar
• Foster DA, Yellen P, Xu L, Saqcena M. Regulation of G1 cell cycle progression: distinguishing the restriction point from a nutrient-sensing cell growth checkpoint(s). Genes Cancer 2010; 1:1124-31; PMID:21779436; http://dx.doi.org/10.1177/1947601910392989
   PubMedGoogle Scholar
• Javanmoghadam-Kamrani S, Keyomarsi K. Synchronization of the cell cycle using lovastatin. Cell Cycle 2008; 7:2434-40; PMID:18677105; http://dx.doi.org/10.4161/cc.6364
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991; 51:3602-9; PMID:1711413
   PubMed Web of Science ®Google Scholar
• Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiology 1988; 62:10J-5J; PMID:3055919; http://dx.doi.org/10.1016/0002-9149(88)90002-1
   PubMed Web of Science ®Google Scholar
• Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 1992; 11:961-71; PMID:1312467
   PubMed Web of Science ®Google Scholar
• O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-8; PMID:16452206; http://dx.doi.org/10.1158/0008-5472.CAN-05-2925
   PubMed Web of Science ®Google Scholar
• Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65:7052-8; PMID:16103051; http://dx.doi.org/10.1158/0008-5472.CAN-05-0917
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129:1261-74; PMID:17604717; http://dx.doi.org/10.1016/j.cell.2007.06.009
   PubMed Web of Science ®Google Scholar
• Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428:332-7; PMID:15029198; http://dx.doi.org/10.1038/nature02369
   PubMed Web of Science ®Google Scholar
• Liu P, Begley M, Michowski W, Inuzuka H, Ginzberg M, Gao D, Tsou P, Gan W, Papa A, Kim BM. Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature 2014; 508:541-5; PMID:24670654; http://dx.doi.org/10.1038/nature13079
   PubMed Web of Science ®Google Scholar
• Stumpf CR, Moreno MV, Olshen AB, Taylor BS, Ruggero D. The translational landscape of the mammalian cell cycle. Mol Cell 2013; 52:574-82; PMID:24120665; http://dx.doi.org/10.1016/j.molcel.2013.09.018
   PubMed Web of Science ®Google Scholar
• Andrs M, Korabecny J, Jun D, Hodny Z, Bartek J, Kuca K. Phosphatidylinositol 3-linase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring. J Med Chem 2014; 8:41-71; PMID:25387153; http://dx.doi.org/10.1021/jm501026z
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010; 29:313-24; PMID:19881548; http://dx.doi.org/10.1038/onc.2009.358
   PubMed Web of Science ®Google Scholar
• Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 2013; 123:3678-84; PMID:23999442; http://dx.doi.org/10.1172/JCI69600
   PubMed Web of Science ®Google Scholar
• Chen Y, Rodrik V, Foster DA. Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene 2005; 24:672-9; PMID:15580312; http://dx.doi.org/10.1038/sj.onc.1208099
   PubMed Web of Science ®Google Scholar
• Leontieva OV, Blagosklonny MV. Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion. Oncotarget 2014; 5:12715-27; PMID:25587030
   PubMed Web of Science ®Google Scholar
• Bitterman PB, Polunovsky VA. eIF4E-mediated translational control of cancer incidence. Biochim Biophys acta 2014; Epub ahead of print; PMID:25263391; http://dx.doi.org/10.1016/j.bbagrm.2014.09.007
   PubMed Web of Science ®Google Scholar
• Sonenberg N. eIF4E, the mRNA cap-binding protein: from basic discovery to translational research. Biochem Cell Biol 2008; 86:178-83; PMID:18443631; http://dx.doi.org/10.1139/O08-034
   PubMed Web of Science ®Google Scholar
• Jackman J, O'Connor PM. Methods for synchronizing cells at specific stages of the cell cycle. Curr Protoc Cell Biol 2001; 8:8.3; PMID:18228388;; 10.1002/0471143030.cb0803s00
   PubMedGoogle Scholar